Long-Term Outcomes of Patients With TR Undergoing MViV Replacement | NCDR Study – American College of Cardiology
Patients undergoing transseptal mitral valve-in-valve (MViV) r eplacement with preprocedural severe or greater tricuspid regurgitation (TR), 30-day residual severe or greater TR, and unchanged or worsened TR post procedure, had a greater risk of all-cause mortality at the three-year follow-up, according to a study published June 9 in JACC: Cardiovascular Interventions. Kashish Goel, MD, FACC, et al., used data from the STS/ACC TVT Registry and included 4,938 patients (21% with severe or greater TR at
